The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option

Daniel El Fassi, Claus H. Nielsen, Hans C. Hasselbalch, Laszlo Hegedüs

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

    Abstrakt

    We have reviewed the immunology of thyroid autoimmunity with special reference to the importance of B lymphocytes (B cells) in thyroidal and extrathyroidal Graves' disease (GD), thus providing a framework for the hypothesis that B cell depletion may be beneficial in GD. Additionally, after reviewing the efficacy and safety in other autoimmune diseases, we propose that treatment with the B cell- depleting agent Rituximab may become a clinically relevant treatment option in selected cases of GD, particularly when complicated with thyroid-associated ophthalmopathy.

    OriginalsprogEngelsk
    Sider (fra-til)623-632
    Antal sider10
    TidsskriftEuropean Journal of Endocrinology
    Vol/bind154
    Udgave nummer5
    DOI
    StatusUdgivet - 1 maj 2006

    Fingeraftryk

    Udforsk hvilke forskningsemner 'The rationale for B lymphocyte depletion in Graves' disease. Monoclonal anti-CD20 antibody therapy as a novel treatment option' indeholder.

    Citationsformater